TCRγ9/δ2(OT3)-Fc融合蛋白体内抗肿瘤效果研究  

Anti-tumor Effect of TCRγ9 /δ2( OT3)-Fc in Nude Mice Bearing Tumor

作　　者：郭阳[1,2] 郑静[2] 胡愉[2] 崔莲仙[2] 何维[2] 

机构地区：[1]湖北医药学院基础医学院免疫教研室,湖北十堰442000 [2]北京协和医学院基础学院中国医学科学院基础医学研究所免疫学系,北京100005

出　　处：《湖北医药学院学报》2014年第2期106-109,F0002,共5页Journal of Hubei University of Medicine

基　　金：国家高技术研究发展计划(863)项目(2006AA02A245)

摘　　要：目的:研究TCRγ9/δ2(OT3)-Fc融合蛋白在体内抗肿瘤效果。方法:通过同位素99mTc标记技术观察TCRγ9/δ2(OT3)-Fc在荷瘤裸鼠体内的显像和分布,观察TCRγ9/δ2(OT3)-Fc对荷瘤裸鼠肿瘤生长和生存期的影响。结果:在荷瘤裸鼠体内99mTc-TCRγ9/δ2(OT3)-Fc与肿瘤组织有明显的结合,并且其可抑制荷瘤裸鼠肿瘤生长速度,延长小鼠生存期。结论:本研究初步证实TCRγ9/δ2(OT3)-Fc在荷瘤裸鼠体内有一定的抗肿瘤效果,为肿瘤靶向性抗体治疗提供了新的思路。Objective To investigate the anti-tumor effects of TCRγ9/δ2（OT3）-Fc fusion protein in vivo. Methods We observed the imaging and distribution of TCRγ9/δ2（OT3）-Fc in nude mice bearing tumor through labeling 99mTcFe. Mean-while, we observed the tumor growth and survival of nude mice with the treatment of TCRγ9/δ2（OT3）-Fc. Results In nude mice 99mTc-TCRγ9/δ2（OT3）-Fc had obvious binding ability with tumor tissue and it inhibited tumor growth in nude mice and prolonged survival of mice. Gorlclusiorl Our preliminary study demonstrats the anti-tumor effect of TCRγ9/δ2（OT3）-Fc in nude mice bearing tumor and this study provides a novel strategy for tumor targeting antibody therapy.

关 键 词：TCRγ9 δ2(OT3)-Fc 肿瘤靶向治疗 荷瘤裸鼠 

分 类 号：R730.5[医药卫生—肿瘤]